Phase 1 Neurology Deal Benchmarks

Median Upfront

$112M

Range: $45M - $185M

Total Deal Value

$1.6B

Range: $811M - $2.4B

Royalty Rate

7.4% - 14.8%

Tiered up to 18.8%

Dev Milestones

$755M

Range: $383M - $1.1B

Model Your Deal

Market Analysis

Phase 1 neurology licensing deals carry a median total deal value of $1.6B, with upfront payments ranging from $45M to $185M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 7% to upfront and 93% to milestones.

The neurology landscape at the phase 1 stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $755M, regulatory milestones contribute $453M, and commercial milestones reach $302M. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for phase 1 neurology deals range from 7.4% to 14.8% at the base tier, with high-tier escalation to 18.8%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1 neurology deals?

Phase 1 neurology deals average $112M in upfront payments, ranging from $45M to $185M. The upfront allocation of 7% of total deal value reflects the clinical stage risk profile.

How are phase 1 neurology deal milestones structured?

Milestones account for approximately 93% of total deal value. Development milestones ($755M) represent the largest component, followed by commercial milestones ($302M) and regulatory milestones ($453M).

What royalty rates are typical for phase 1 neurology licensing?

Base royalty rates range from 7.4% to 14.8%, with tiered escalation to 11.4%-18.8% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Neurology Deals

Phase 1/2 Neurology Deals

Phase 1 Oncology Deals

Phase 1 Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?

Need the full deal landscape?